BioNTech develops immunotherapies for cancer and other diseases. Co.'s immunotherapy product candidates span the following four drug classes: messenger ribonucleic acid (mRNA) therapeutics, in which it is utilizing mRNA to deliver genetic information to cells; cell therapies, in which it is developing a range of cell therapies, including chimeric antigen receptorT cells, neoantigen-based T cell therapies and T cell receptor therapies; antibodies, in which it is developing antibodies that are designed to target immune checkpoints that modulate the patient's immune response to cancer; and small molecule immunomodulators, which is for the treatment of solid tumors in clinical testing.
|
Free BNTX Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Buy (2.71 out of 4) 14th percentile
(ranked lower than approx. 86% of all stocks covered)
Analysts' Target Price: BNTX Stock Forecast Based on Zacks ABR data; powered by Xignite |